2021-01-11,"Benzinga's Top Upgrades, Downgrades For January 11, 2021"
2020-12-29,Tuesdays 10 Notable Market Movers in the Limelight
2020-12-29,"UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021"
2020-12-29,"BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021"
2020-12-17,BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
2020-12-10,BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
2020-11-29,"Do Hedge Funds Love BeyondSpring, Inc. (BYSI)?"
2020-11-24,BeyondSpring to Present at Two Upcoming Scientific Conferences in December
2020-11-23,BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
2020-11-19,BeyondSpring Announces Pricing of Ordinary Shares
2020-11-17,BeyondSpring Announces Proposed Public Offering of Ordinary Shares
2020-11-17,BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
2020-11-16,BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia
2020-11-13,BeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference
2020-11-13,"BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly"
2020-10-14,Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
2020-10-12,BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
2020-09-29,JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
2020-09-24,"New Data Highlights BeyondSprings Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19"
2020-09-22,BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
2020-09-22,What Type Of Shareholders Own The Most Number of BeyondSpring Inc. (NASDAQ:BYSI) Shares?
2020-09-11,"BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference  on September 14, 2020"
2020-09-10,BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session
2020-09-08,BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
2020-09-03,BeyondSpring Inc. (BYSI) Q2 2020 Earnings Call Transcript
2020-09-03,BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
2020-08-27,"BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020"
2020-08-18,"BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors"
2020-08-11,BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
2020-06-30,New Stem Cell-Based Application for BeyondSprings Plinabulin Presented at ISSCR Annual Meeting
2020-06-24,BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%
2020-06-23,New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSprings Plinabulin
2020-06-19,BeyondSpring Announces Pricing of Ordinary Shares
2020-06-18,BeyondSpring Announces Proposed Public Offering of Ordinary Shares
2020-06-15,BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention
2020-06-11,BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update
2020-06-09,BeyondSprings PROTECTIVE-2 (Study 106) Phase 2 Trial for Chemotherapy-Induced Neutropenia Shows Positive Results in Chemotherapy Optimization with Potentially Better Clinical Outcomes
2020-06-03,BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification
2020-06-02,BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program
2020-05-13,BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients
2020-05-01,BeyondSpring Inc. (BYSI) Q4 2019 Earnings Call Transcript
2020-04-30,BeyondSpring Files 2019 Annual Report on Form 20-F
2020-04-30,BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update
2020-04-29,FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study
2020-04-23,"BeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update Conference Call on April 30, 2020"
2020-03-30,BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia
2020-03-26,One Thing To Remember About The BeyondSpring Inc. (NASDAQ:BYSI) Share Price
2020-03-23,BeyondSprings Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy
2020-03-11,BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19
2020-02-10,BeyondSprings Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients
2020-01-23,BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Companys Board of Directors
2020-01-06,BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China
2019-12-19,BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies
2019-12-18,BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update
2019-12-11,"BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019"
2019-12-10,BeyondSprings Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting
2019-12-09,BeyondSprings Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulins Mechanism of Action for CIN Accepted at American Society of Hematologys 2019 Annual Meeting
2019-11-11,BeyondSprings Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019
2019-11-06,"BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources"
2019-10-25,BeyondSpring Announces Pricing of Ordinary Shares
2019-10-24,BeyondSpring Announces Proposed Public Offering of Ordinary Shares
2019-10-23,BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia
2019-10-17,"BeyondSprings Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors"
2019-10-08,"Cell Journals Publishes BeyondSprings New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation"
2019-10-01,BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019
2019-09-26,What Kind Of Shareholders Own BeyondSpring Inc. (NASDAQ:BYSI)?
2019-09-23,BeyondSprings Plinabulin Continues to Build on Superior Product Profile in Breast Cancer Trial for Neutropenia Prevention
2019-09-18,BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results
2019-09-18,"BeyondSpring, Inc. to Host Earnings Call"
2019-09-11,"BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019"
2019-09-10,BeyondSprings Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer
2019-09-06,BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference
2019-08-23,BeyondSprings Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia
2019-07-17,BeyondSpring Announces Pricing of Public Offering of Ordinary Shares
2019-07-16,BeyondSpring Announces Proposed Public Offering of Ordinary Shares
2019-07-10,BeyondSpring Provides Operational Update and First Quarter 2019 Financial Results
2019-06-28,18 Stocks Joining The Russell Indices
2019-06-20,BeyondSpring Set to Join FTSE Russell 3000® Index
2019-06-04,BeyondSpring to Present at the Jefferies 2019 Healthcare Conference
2019-05-20,"BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019"
2019-05-16,BeyondSprings Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
2019-04-30,BeyondSpring Files 2018 Annual Report on Form 20-F
2019-04-30,BeyondSpring Inc. (BYSI) Q4 2018 Earnings Call Transcript
2019-04-30,BeyondSpring Provides Business Update and Fourth Quarter and Full-Year 2018 Financial Results
2019-04-30,"BeyondSpring, Inc. to Host Earnings Call"
2019-04-24,"BeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and Operational Update Conference Call on April 30, 2019"
2019-04-04,BeyondSpring to Present at the 18th Annual Needham Healthcare Conference
2019-03-26,"BeyondSprings Lead Asset, Plinabulin, Shifts the Balance of Macrophages Towards Anti-Cancer M1s"
2019-03-25,BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
2019-03-20,"BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference"
2019-03-05,BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
2019-02-26,New Data Shows Addition of BeyondSprings Plinabulin Reverses Neulastas Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia
2019-01-17,How to spot risky biotech companies and six to avoid now
2018-12-27,"BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin"
2018-12-21,United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSprings Lead Asset Plinabulin with Protection to 2036
2018-12-06,BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
2018-12-04,"Data for BeyondSprings Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF"
2018-11-30,Can The Uptrend Continue for BeyondSpring (BYSI)?
2018-11-27,Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia
2018-11-21,"Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook  Fundamental Analysis, Calculating Forward Movement"
